1、稀缺标的价值释放正当时 从市场环境来看，2025年以来港股IPO市场火热，投资者情绪回升，有望支持基本面优秀，具有较高内在价值的企业实现较好的估值表现，布鲁可、蜜雪冰 城等现象级IPO的出现就是直观的证明。 同时，资本市场对低碳、合成生物赛道预期升温，包括ESG投资持续发展，也提供出有利的外部环境。 这些均有望支撑首钢朗泽的价值释放，充分展现出稀缺性标的的投资价值。 港股新股市场即将迎来又一稀缺标的。 7月7日，首钢朗泽重启招股。 作为碳捕集、利用和封存（CCUS）行业首家利用经过验证的合成生物技术实现低碳产品生产商业化的公司，首钢朗泽具备独特的商业范式，上市后将为港 股ESG概念股注入新的活力。 这也呈现出多维度的价值张力，清晰勾勒其投资亮点，值得投资者留意。 2、行业首家，享有先发优势 从业务模式来看，根据弗若斯特沙利文的资料，首钢朗泽是CCUS行业中首家利用经过验证的合成生物技术实现低碳产品生产商业化的公司，这使其能够在 全球环保减碳机遇面前享有先发优势，具备可观的增长潜力。 如今，全球各大经济体高度重视碳中和，制定清晰的减碳和碳净零目标，正催生数倍增长的碳减排需求。弗若斯特沙利文的资料显示，全球C ...

Group 1 - Industry Investment Rating: Overweight [1] - Core Viewpoint: The chemical sector's overall performance ranked 16th with a fluctuation of 0.80%, underperforming the Shanghai Composite Index by 0.60 percentage points [4][22] - Key Recommendations: Focus on synthetic biology, pesticides, chromatography media, sugar substitutes, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Group 2 - Synthetic Biology: A pivotal moment is approaching, with low-energy products expected to gain a longer growth window due to the energy structure adjustment [4] - Refrigerants: The third-generation refrigerants are entering a high prosperity cycle, with supply constraints and stable demand growth anticipated [5] - Electronic Specialty Gases: The domestic market faces a contradiction between rapid upgrades in wafer manufacturing and insufficient high-end electronic specialty gas capacity, presenting significant domestic substitution opportunities [6][8] - Light Hydrocarbon Chemicals: A global trend towards lighter raw materials in the olefin industry is noted, with a shift from heavy naphtha to lighter ethane and propane [8] - COC Polymers: The domestic industrialization process is accelerating, driven by breakthroughs in local enterprises and a shift in downstream industries to domestic production [9] - Potash Fertilizer: Prices are expected to bottom out and rebound due to supply reductions and increased demand from farmers [10] - MDI Market: The oligopoly structure is expected to improve, with demand steadily increasing and a favorable supply outlook anticipated [12]

近年来，生物制造已作为多数国家提升经济竞争力的着力点，也是我国继绿色制造、智能制造后，推进制造强国建设的又一重要抓手。同时，各地政府 地区通过结合自身优势力争实现合成生物"研发－转化－产业—集群"协同发展，发挥新质生产力 作用。 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2 025 ) 。大会 聚焦" 1+4 " ： AI+生 物智造 这一大热门赛道； 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ，邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ； 哪些革新技术和产品将给生物制造产业带来持续的生命力 ； 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主办单位： 宁波德泰中研信息科技有限公司（ DT 新材料） 协办 单位： 宁波酶赛生物工程有限公司 二、大会亮点 三、大会日程 亮点一 ： 大会论坛、闭门活动洞察"十五五"生物制造发展趋势！探索新产品、新技术、新落地、 新合作！ 亮点二： 青年创新技术与价值分享、人才对接与合作！ 亮 ...

项目拟投资3亿，建设综合楼、研发中心、库房、车间、门卫、监控室、消防控制室及相关能源配套系统。项目建成年产3万吨功能性糖醇。 瑞 芬生物作为D-阿洛酮糖-3-差向异构酶在国内 第三家获批 的企业，标志着其在功能性代糖领域的突出技术突破。其突破不仅体现在阿洛酮糖的合 法化生产，更核心的是在酶催化技术这一关键环节实现了自主可控 。 项目进展 | 瑞芬生物 【SynBioCon】 获 悉 ， 近日，内蒙古瑞芬生物科技有限公司 年产3万吨功能糖醇生产基地项目 在相关网站备案公示。 据悉，4月26日,呼和浩特经济技术开发区与北京瑞芬生物科技有限公司签署《瑞芬生物合成生物产业基地项目》合作协议书。此次签约项目总投资约 4亿元，分两期建设年产2万吨糖醇生产基地，一期计划用地120亩，于今年6月开工，2025年11月完成基础建设，2026年3月正式投产。 瑞芬生物创新研发中心(IDEALab)设立于北京，现有3个生产基地，分别位于陕西杨凌、安徽滁州和山东曲阜。 目前滁州基地阿洛酮糖1千吨，待投 产能1万吨，赤藓糖醇产能1.5万吨 。 关于瑞芬生物 成立于2007年，是国家级高新技术企业，始终致力于天然健康食品配料及配料系统的 ...

【SynBioCon】 获 悉，7月2日，北京首钢朗泽科技股份有限公司（简称"首钢朗泽"）发布公告称， 全球发售及上市计划延迟，将退回申请股款 。 6月 27日，首钢朗泽通过港交所主板上市聆讯，并原定于7月9日在港交所挂牌上市。 首钢朗泽公告称， 6月27日，公司收到一份民事起诉状， 公司被列为被告。 公司拟将所得款项净额约37.9%用于资助在中国内蒙古包头建设和开发 SAF 生产设施，21.2%用于河北首朗二期设施，11.4%用于 菌株、生产设备及工 艺以及智能生产管理系统 的研究与开发，14.1%用于四个生产设施的技术升级，5.3%用于新产品的开发，10%用于一般公司用途和营运资金需求。 图片来源：公司公告 该公司原定计划发行约2,016万股H股，一成于香港作公开发售，招股价介乎14.5港元至18.88港元，集资最多3.8亿港元，每手200股，一手入场费 3,814.1港元。国泰君安国际为独家保荐人。目前认购反应平平，孖展仅录超购5.41倍。 首钢朗泽是一家从事碳捕集、利用和封存行业（亦称为CCUS行业）的公司，主要专注于 通过碳捕集和利用技术生产乙醇及微生物蛋白等低碳产品，并 提供低碳综合性解决方案 。 ...

①固态电池+海工装备+光刻机+芯片概念！这家公司获得半导体掩模版直写光刻机订单，与客户在固态电 池方面有相关接洽合作；②人形机器人+海工装备+核电+数据中心！这家公司有人形机器人和机器狗相关 线缆订单；③减肥药+合成生物+CRO！公司公司多肽原料药产能达到吨级。 前言 每周日至每周四推送明日股市重大公告！内容包含"停复牌、增减持、投资中标、收购、业绩、解禁、 高送转"等一系列个股利好利空公告，其中重要公告均以红色标注，帮助投资者提前寻找到投资热点， 防范各类黑天鹅事件，并且有充足的时间进行分辨和寻找合适的上市公司。 ...

6月19日，在"活力中国调研行"采访团来到微元合成生物技术（北京）有限公司时，微元合成阿洛酮糖 还正在审批中。 "如果我们的工作，能够给人们的生活带来一些改变，哪怕是一点点儿，也是了不起的成就"，这是刘波 在中科院微生物所工作时，老所长就任时讲的一段话，这也是刘波和他的团队正在努力做的事。 "7月2日，微元合成阿洛酮糖正式获得国家卫生健康委员会新食品原料公告行政许可，成为全国首家获 得批准上市的阿洛酮糖生产企业，也是唯一一家通过生物发酵工艺获批的企业。此次批准的AS10菌株 直接发酵法生产阿洛酮糖技术，是国内首个采用合成生物技术生产的新食品原料获批的案例"。7月2日 上午，在微元合成创始人、CEO刘波的"微信朋友圈"，《金融时报》记者看到这条令人振奋的消息。 据刘波介绍，阿洛酮糖又名无花果糖，是一种口感接近蔗糖、热量却几乎没有的天然稀有糖。阿洛酮糖 可以满足消费者对甜的需求，补充国内食糖的缺口，但不会带来身体代谢的负担，同时对血糖控制和体 重管理还有积极作用。 据微元合成首席运营官李响介绍，蔗糖也是一种常见的大宗药用辅料。八包板蓝根颗粒曾把一名成年男 性"送进"ICU，就是因为短时间内摄入过多糖分，这名有糖尿 ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on the development trends and growth points of biomanufacturing, with 30 industry leaders and experts invited [7]. - The second and third days will include a macro forum on biomanufacturing, specialized sub-forums on green chemicals, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. Group 4: Focus Areas in Sub-forums - Sub-forum topics include the development of bio-based chemicals, green manufacturing technologies for fine chemicals, and the use of non-food raw materials for high-value product development [11]. - AI applications in biomanufacturing will also be discussed, including enzyme discovery and industrial fermentation process control [11].

Core Viewpoint - Guangdong Zhumei Biotechnology has achieved a significant breakthrough in the industrialization of natural high-intensity sweet protein by completing the first domestic pilot test of recombinant Brazzein using Pichia pastoris as the chassis cell, aiming for ton-level production capacity by 2026, which will greatly increase the yield of Brazzein [1][2]. Group 1: Characteristics of Brazzein - Brazzein is derived from the fruit of a wild plant in West Africa and is known to be 500-2000 times sweeter than sucrose, making it one of the sweetest natural substances known to humans [4]. - It maintains stability across a pH range of 2.5-8 and retains its sweetness even after being heated at 80°C for 4 hours or 98°C for 2 hours [5]. - As a protein, Brazzein is easily digested into amino acids, has no impact on blood sugar, and poses no health risks [6]. - It offers a clean taste similar to sucrose without metallic or bitter aftertastes, making it suitable for widespread application in the food industry [6]. - Research indicates that Brazzein may possess anti-inflammatory and antioxidant properties, with similarities to antimicrobial peptides, providing some antibacterial and antifungal activity [6]. Group 2: Market Potential and Challenges - The global market for Brazzein was valued at $500 million in 2023 and is projected to reach $790 million by 2029 [7]. - Traditional extraction methods yield very low extraction rates (~0.2%), making precision fermentation and genetic engineering the most promising methods for developing Brazzein [7]. - Current microbial expression systems face challenges such as low protein expression levels, incorrect protein folding leading to reduced activity, and complex, costly purification processes, which limit the widespread application of sweet proteins [9]. Group 3: Industry Developments - In May 2023, Sweegen successfully produced Brazzein using precision fermentation and became the first to receive FEMA GRAS certification [11]. - In 2024, Oobli's Brazzein production received FDA GRAS certification for general food applications, and they announced a partnership with Ingredion to advance sweet protein applications [11]. - Ginkgo Bioworks and GreenLab are collaborating to enhance Brazzein expression in corn and scale up production through precision fermentation [11]. - Waterdrop Farm also achieved FDA SELF-GRAS status in March 2025, becoming one of the few companies to commercialize Brazzein [11]. Group 4: Company Overview - Guangdong Zhumei Biotechnology is a high-tech enterprise specializing in the research, production, and sales of synthetic biology products, with a 1000 square meter intelligent research center [12]. - The company utilizes synthetic biology technology to efficiently produce various products, including recombinant human collagen, astaxanthin, beta-carotene, antimicrobial peptides, and lysozyme [12].

Core Viewpoint - The article discusses the upcoming SynBioCon 2025 conference, focusing on the research and industrial applications of poly-γ-glutamic acid (γ-PGA), a biopolymer with significant potential in various fields such as functional foods, cosmetics, biomedicine, and biomaterials [1][3]. Summary by Sections γ-PGA Characteristics and Applications - γ-PGA's physiological functions and application areas are highly dependent on the proportion of L-glutamic acid monomers and molecular weight, with low molecular weight γ-PGAs (Mw<500 kDa) suitable for drug delivery and tissue engineering, while high molecular weight γ-PGAs (Mw>1500 kDa) serve as thickeners or flocculants [2]. Industrial Biotechnology Challenges - The efficient biosynthesis of γ-PGA from scratch and the directed synthesis of γ-PGA with varying L-glutamic acid monomer ratios and molecular weights are critical industrial biotechnology challenges that need to be addressed [3]. SynBioCon 2025 Conference Details - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, Zhejiang, focusing on the intersection of AI and biological manufacturing, as well as advancements and opportunities in green chemicals, new materials, future foods, future agriculture, and cosmetic raw materials [7][8]. - The conference will feature a special session, the "Youth Forum on Biological Manufacturing," aimed at providing insights into scientific issues, solutions, results, scalability, and future directions in the research field [7][8]. Conference Agenda - The agenda includes registration, a closed-door seminar for industry leaders, project roadshows, and various forums covering topics such as green chemicals, new materials, and future foods and agriculture [8][10].